Abstract
Ischemia/reperfusion injury is unavoidable during cardiopulmonary bypass surgery because the surgery is conducted during ischemic arrest of the heart. Animal studies have shown that the administration of angiotensin converting enzyme (ACE) inhibitors can protect against lethal arrhythmias, preserve ventricular function, and improve coronary reserve after ischemia/reperfusion. Two factors to consider when using ACE inhibitors are their temperature dependency (because cardiopulmonary bypass surgery is usually done under hypothermic conditions) and their direct effect on the bypass material. In this paper, we review studies of ACE inhibitors and discuss both their temperature dependency and their effect on bypass material, especially on the coating of the circuit tube and artificial lung. Finally, we explore the potential clinical applications of ACE inhibitors in cardiopulmonary bypass surgery, taking into consideration the findings of our own preliminary clinical study.
Keywords: ace inhibitor, cardiopulmonary bypass, heart surgery, biocompatibility, bradykinin, angiotensin, review
Current Enzyme Inhibition
Title: Angiotensin Converting Enzyme Inhibitors and Cardiopulmonary Bypass: Is ACE Inhibitor Safe for Heart Surgery?
Volume: 1 Issue: 3
Author(s): Yasuyuki Shimada and Hideshi Itoh
Affiliation:
Keywords: ace inhibitor, cardiopulmonary bypass, heart surgery, biocompatibility, bradykinin, angiotensin, review
Abstract: Ischemia/reperfusion injury is unavoidable during cardiopulmonary bypass surgery because the surgery is conducted during ischemic arrest of the heart. Animal studies have shown that the administration of angiotensin converting enzyme (ACE) inhibitors can protect against lethal arrhythmias, preserve ventricular function, and improve coronary reserve after ischemia/reperfusion. Two factors to consider when using ACE inhibitors are their temperature dependency (because cardiopulmonary bypass surgery is usually done under hypothermic conditions) and their direct effect on the bypass material. In this paper, we review studies of ACE inhibitors and discuss both their temperature dependency and their effect on bypass material, especially on the coating of the circuit tube and artificial lung. Finally, we explore the potential clinical applications of ACE inhibitors in cardiopulmonary bypass surgery, taking into consideration the findings of our own preliminary clinical study.
Export Options
About this article
Cite this article as:
Shimada Yasuyuki and Itoh Hideshi, Angiotensin Converting Enzyme Inhibitors and Cardiopulmonary Bypass: Is ACE Inhibitor Safe for Heart Surgery?, Current Enzyme Inhibition 2005; 1 (3) . https://dx.doi.org/10.2174/157340805774580475
DOI https://dx.doi.org/10.2174/157340805774580475 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Protective Effects of Astragalus Membranaceus and Ligustrazine on Rat Brain Microvascular Endothelial Cell Injury after Oxygen-Glucose Deprivation/ Reoxygenation by Suppressing the PKCδ/MARCKS Pathway
Combinatorial Chemistry & High Throughput Screening The Bioanalytical Molecular Pharmacology of the N-methyl-<sub>D</sub>-Aspartate (NMDA) Receptor Nexus and the Oxygen-Responsive Transcription Factor HIF-1α : Putative Mechanisms and Regulatory Pathways Unravel the Intimate Hypoxia Connection
Current Molecular Pharmacology Interleukin-4-Induced Oxidative Stress Via Microglial NADPH Oxidase Contributes to the Death of Hippocampal Neurons In Vivo
Current Aging Science Protective Effect of Natural Antioxidants on Heart Against Ischemia-Reperfusion Damage
Current Pharmaceutical Biotechnology A Molecular Link Between Diabetes and Breast Cancer: Therapeutic Potential of Repurposing Incretin-based Therapies for Breast Cancer
Current Cancer Drug Targets Carbohydrates and Epithelial Repair - More Than Just Post-Translational Modification
Current Drug Targets Technetium-99m Cysteine; A Novel Radiopharmaceutical for Detection of Experimental Myocardial Infarction in Rats
Current Radiopharmaceuticals The Immunosuppressive Agent FK506 Prevents Subperineurial Degeneration and Demyelination on Ultrastructural and Functional Analysis
Current Neurovascular Research Pre-Emptive Conditioning of the Ischemic Heart
Cardiovascular & Hematological Agents in Medicinal Chemistry Astrocyte Influences on Ischemic Neuronal Death
Current Molecular Medicine In Silico Identification of Potential Dynamin-Related Protein 1 Antagonists: Implications for Diseases Involving Mitochondrial Dysfunction
Combinatorial Chemistry & High Throughput Screening Natural Plant Extracts as Potential Therapeutic Agents for the Treatment of Cancer
Current Topics in Medicinal Chemistry Editorial: Recent Advances of Cell and Gene Therapy in Kidney Diseases
Current Gene Therapy Structure Activity Relationships for Nicotinamide in the Treatment of Stroke
Letters in Drug Design & Discovery TRPV1 Activation Prevents Renal Ischemia-Reperfusion Injury-Induced Increase in Salt Sensitivity by Suppressing Renal Sympathetic Nerve Activity
Current Hypertension Reviews Interleukin-1 Drives Cerebrovascular Inflammation via MAP Kinase-Independent Pathways
Current Neurovascular Research Dibenzofurans from Lichens – A Pharmacological Overview
Current Topics in Medicinal Chemistry MCP-1/CCL2 as a Therapeutic Target in Myocardial Infarction and Ischemic Cardiomyopathy
Inflammation & Allergy - Drug Targets (Discontinued) Glycogen Synthase Kinase-β3 in Ischemic Neuronal Death
Current Neurovascular Research Regenerative Approaches to Post-Myocardial Infarction Heart Failure
Current Pharmaceutical Design